Oct 08 2026 10:00 PM EST
AVITA Medical Raises FY 2026 Revenue Guidance as New Products Gain Traction
AVITA Medical, Inc. (NASDAQ: RCEL) posted its strongest quarterly results to date, prompting the stock to climb more than 180% over the past three months. The surge reflects investors’ reassessment of the company’s revenue trajectory, tighter expense discipline and the commercial rollout of its RECELL GO mini, PermeaDerm and Cohealyx product lines.
In Q2 2026 the company reported revenue of $21.7 million, an 18% YoY increase and 13% sequential growth. Gross margin held at 81.9%, while operating expenses fell 6% YoY to $24.6 million. Net loss narrowed to $7.7 million ($0.25 per share) from $10.6 million a quarter earlier. Management raised FY 2026 revenue guidance to $86‑$89 million, up from the prior $80‑$85 million range, and reiterated a target of cash‑flow breakeven in Q4 2026.
Product‑Line Expansion and Reimbursement Momentum
The revenue lift stems from the launch of three new offerings. The RECELL GO mini, cleared by the FDA in December 2024, targets smaller wounds and vitiligo, expanding the addressable market. PermeaDerm, a biosynthetic wound matrix, generated $0.6 million in Q2 2026, a ~40% QoQ increase, while Cohealyx, a bovine‑derived collagen matrix, entered commercial use in early 2025. Positive interim data – a 20‑day reduction in time to skin grafting for Cohealyx and a 70% cost advantage for PermeaDerm – have reinforced clinician adoption.
In parallel, the Centers for Medicare & Medicaid Services (CMS) issued a proposed 2027 Medicare Physician Fee Schedule for RECELL, moving toward a national, transparent reimbursement framework. Finalization is expected later in 2026, with effective date Jan 1 2027, which could reduce payer variability and support a more predictable revenue stream.
Financial Position and Liquidity Improvements
Cash balances rose to $11.1 million at quarter‑end, up from $9.9 million in Q1 2026, while the cash‑burn rate fell to $3.2 million in Q2 2026. The company’s cash runway now extends roughly 3.8 years from the March 2023 baseline, reflecting both higher cash on hand and a reduced burn. Long‑term debt remains at about $50 million at 11.5% interest, with a current ratio of 0.57, indicating that covenant compliance will hinge on continued revenue growth.
Sector Tailwinds and Analyst Sentiment
The regenerative‑medicine market is projected to grow at a 16‑25% compound annual rate through 2030, providing a macro‑level tailwind for AVITA’s wound‑care platform. Consensus forecasts now anticipate revenue growth of 17‑28% per annum for the company, outpacing the roughly 20% industry average cited in recent analyst reports. Accordingly, broker houses have upgraded price targets: BTIG to $11 (Buy), TD Cowen to $14 (Buy), and Zacks now rates the stock as a #2 (Buy). The 12‑month average price target sits between $11.40 and $12.33, supporting a valuation premium relative to peers.
Risks and Uncertainties
Key risks include the company’s leverage and the need to stay above covenant thresholds on its $60 million credit facility. A delay in achieving the projected cash‑flow breakeven could force additional equity dilution. Reimbursement volatility, especially as CMS finalizes the 2027 fee schedule, remains a material uncertainty. Finally, the commercial uptake of PermeaDerm and Cohealyx must scale without eroding the high gross margins historically delivered by the RECELL system.
Investors will watch the upcoming Q3 2026 earnings for confirmation that revenue acceleration and expense discipline persist, and for any update on the timeline to positive EBITDA, which analysts expect around 2028.